These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 9772205)

  • 1. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.
    Nakahara K; Kuriyama M; Sonoda Y; Yoshidome H; Nakagawa H; Fujiyama J; Higuchi I; Osame M
    Toxicol Appl Pharmacol; 1998 Sep; 152(1):99-106. PubMed ID: 9772205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors.
    Sonoda Y; Gotow T; Kuriyama M; Nakahara K; Arimura K; Osame M
    Muscle Nerve; 1994 Aug; 17(8):891-7. PubMed ID: 8041396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
    Smith PF; Eydelloth RS; Grossman SJ; Stubbs RJ; Schwartz MS; Germershausen JI; Vyas KP; Kari PH; MacDonald JS
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1225-35. PubMed ID: 1904494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.
    Pierno S; De Luca A; Tricarico D; Roselli A; Natuzzi F; Ferrannini E; Laico M; Camerino DC
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1490-6. PubMed ID: 8531120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits.
    Fukami M; Maeda N; Fukushige J; Kogure Y; Shimada Y; Ogawa T; Tsujita Y
    Res Exp Med (Berl); 1993; 193(5):263-73. PubMed ID: 8278673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment.
    Duncan AJ; Hargreaves IP; Damian MS; Land JM; Heales SJ
    Toxicol Mech Methods; 2009 Jan; 19(1):44-50. PubMed ID: 19778232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy.
    Mullen PJ; Lüscher B; Scharnagl H; Krähenbühl S; Brecht K
    Biochem Pharmacol; 2010 Apr; 79(8):1200-9. PubMed ID: 20018177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats.
    Reijneveld JC; Koot RW; Bredman JJ; Joles JA; Bär PR
    Pediatr Res; 1996 Jun; 39(6):1028-35. PubMed ID: 8725265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity.
    Seachrist JL; Loi CM; Evans MG; Criswell KA; Rothwell CE
    Toxicol Sci; 2005 Dec; 88(2):551-61. PubMed ID: 16141437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model.
    El-Ganainy SO; El-Mallah A; Abdallah D; Khattab MM; Mohy El-Din MM; El-Khatib AS
    Toxicology; 2016 Jun; 359-360():29-38. PubMed ID: 27345130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study.
    Jasińska M; Owczarek J; Orszulak-Michalak D
    Acta Pol Pharm; 2006; 63(5):386-90. PubMed ID: 17357590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats.
    Schaefer WH; Lawrence JW; Loughlin AF; Stoffregen DA; Mixson LA; Dean DC; Raab CE; Yu NX; Lankas GR; Frederick CB
    Toxicol Appl Pharmacol; 2004 Jan; 194(1):10-23. PubMed ID: 14728975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle.
    Pierno S; De Luca A; Liantonio A; Camerino C; Conte Camerino D
    Eur J Pharmacol; 1999 Jan; 364(1):43-8. PubMed ID: 9920183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin: characterization of induced myopathy in the rat.
    Westwood FR; Scott RC; Marsden AM; Bigley A; Randall K
    Toxicol Pathol; 2008 Feb; 36(2):345-52. PubMed ID: 18362199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia.
    Draeger A; Monastyrskaya K; Mohaupt M; Hoppeler H; Savolainen H; Allemann C; Babiychuk EB
    J Pathol; 2006 Sep; 210(1):94-102. PubMed ID: 16799920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
    Nishimoto T; Ishikawa E; Anayama H; Hamajyo H; Nagai H; Hirakata M; Tozawa R
    Toxicol Appl Pharmacol; 2007 Aug; 223(1):39-45. PubMed ID: 17599378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental simvastatin-induced myopathy in rabbits.
    Nakahara K; Kuriyama M; Yoshidome H; Nagata K; Nagado T; Nakagawa M; Arimura K; Higuchi I; Osame M
    J Neurol Sci; 1992 Nov; 113(1):114-7. PubMed ID: 1469449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin-induced myopathy in a patient treated for hypercholesterolemia. Morphological aspects.
    Wicher-Muniak E; Zmudka K; Dabroś W; Dudek D; Stachura J
    Pol J Pathol; 1997; 48(1):69-74. PubMed ID: 9200964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients.
    Meriggioli MN; Barboi AC; Rowin J; Cochran EJ
    J Clin Neuromuscul Dis; 2001 Mar; 2(3):129-34. PubMed ID: 19078619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin.
    Thelen KM; Rentsch KM; Gutteck U; Heverin M; Olin M; Andersson U; von Eckardstein A; Björkhem I; Lütjohann D
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1146-52. PubMed ID: 16282522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.